**Therapeutic Class Code:** H3F  
**Therapeutic Class Description:** Migraine Therapy - Calcitonin Gene-Related Peptide Inhibitors

<table>
<thead>
<tr>
<th>Medication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preventative treatment of migraines in adults:</td>
</tr>
<tr>
<td>Aimovig 70mg/ml autoinjector</td>
</tr>
<tr>
<td>Aimovig 140mg/ml autoinjector</td>
</tr>
<tr>
<td>Ajovy 225mg/1.5ml autoinjector</td>
</tr>
<tr>
<td>Ajovy 225mg/1.5ml syringe</td>
</tr>
<tr>
<td>Emgality 120mg/ml pen</td>
</tr>
<tr>
<td>Emgality 120mg/ml syringe</td>
</tr>
<tr>
<td>Emgality 120mg/ml pen</td>
</tr>
<tr>
<td>Nurtec ODT 75 mg tablets</td>
</tr>
<tr>
<td>Qulipta tablets</td>
</tr>
<tr>
<td>Vyepti 100 mg/ml vial</td>
</tr>
<tr>
<td>Treatment of episodic cluster headache in adults</td>
</tr>
<tr>
<td>Emgality 100mg/ml syringe (set of 3)</td>
</tr>
<tr>
<td>Acute Treatment of Migraines, with or without aura</td>
</tr>
<tr>
<td>Nurtec ODT 75 mg tablets</td>
</tr>
<tr>
<td>Ubrelvy 50 mg tablets</td>
</tr>
<tr>
<td>Ubrelvy 100 mg tablets</td>
</tr>
</tbody>
</table>

**Eligible Beneficiaries**  
NC Medicaid (Medicaid) beneficiaries shall be enrolled on the date of service and may have service restrictions due to their eligibility category that would make them ineligible for this service.

NC Health Choice (NCHC) beneficiaries, ages 6 through 18 years of age, shall be enrolled on the date of service to be eligible, and must meet policy coverage criteria, unless otherwise specified. **EPSDT does not apply to NCHC beneficiaries.**

**EPSDT Special Provision: Exception to Policy Limitations for Beneficiaries under 21 Years of Age**

**42 U.S.C. § 1396d(r) [1905(r) of the Social Security Act]**

Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) is a federal Medicaid requirement that requires the state Medicaid agency to cover services, products, or procedures for Medicaid beneficiaries under 21 years of age if the service is **medically necessary health care** to correct or ameliorate a defect, physical or mental illness, or a condition [health problem] identified through a screening examination (includes any evaluation by a physician or other licensed clinician). This means EPSDT covers most of the medical or remedial care a child needs to improve or maintain his/her health in the best condition possible, compensate for a health problem, prevent it from worsening, or prevent the development of additional health problems. Medically necessary services will be provided in the most economic mode, as long as the treatment made available is similarly efficacious to the service requested by the beneficiary’s physician, therapist, or other licensed practitioner; the determination process does not delay the delivery of the needed service; and the determination does not limit the beneficiary’s right to a free choice of providers.

04/01/2022
EPSDT does not require the state Medicaid agency to provide any service, product, or procedure
a. that is unsafe, ineffective, or experimental/investigational.
b. that is not medical in nature or not generally recognized as an accepted method of medical
   practice or treatment.

Service limitations on scope, amount, duration, frequency, location of service, and/or other specific
criteria described in clinical coverage policies may be exceeded or may not apply as long as the
provider’s documentation shows that the requested service is medically necessary “to correct or
ameliorate a defect, physical or mental illness, or a condition” [health problem]; that is, provider
documentation shows how the service, product, or procedure meets all EPSDT criteria, including to
correct or improve or maintain the beneficiary’s health in the best condition possible, compensate for a
health problem, prevent it from worsening, or prevent the development of additional health problems.

EPSDT and Prior Approval Requirements
a. If the service, product, or procedure requires prior approval, the fact that the beneficiary is under 21
   years of age does NOT eliminate the requirement for prior approval.

b. IMPORTANT ADDITIONAL INFORMATION about EPSDT and prior approval is found in the
   Basic Medicaid and NC Health Choice Billing Guide, sections 2 and 6, and on the EPSDT provider
   page. The Web addresses are specified below.

   NCTracks Provider Claims and Billing Assistance Guide:
   https://www.nctracks.nc.gov/content/public/providers/provider-manuals.html

   EPSDT provider page:
   https://medicaid.ncdhhs.gov/medicaid/get-started/find-programs-and-services-right-you/medicaid-
   benefit-children-and-adolescents

Health Choice Special Provision: Exceptions to Policy Limitations for Health Choice Beneficiaries
   ages 6 through 18 years of age

EPSDT does not apply to NCHC beneficiaries. If a NCHC beneficiary does not meet
the clinical coverage criteria within the Outpatient Pharmacy prior approval clinical
coverage criteria, the NCHC beneficiary shall be denied services. Only services included
under the Health Choice State Plan and the DMA clinical coverage policies, service
definitions, or billing codes shall be covered for NCHC beneficiaries.

A. Preventative Treatment of Migraines (Aimovig, Ajovy, Emgality 120mg/ml, Nurtec ODT,
   Qulipta, and Vyepti)

   Initial Criteria for Coverage
   1. Beneficiary has a diagnosis of migraine with or without aura based on International Classification of
      Headache Disorders criteria;

   2. Beneficiary is 18 years old or older;
Migraine Therapy

Calcitonin Gene-Related Inhibitors

3. Beneficiary does not have medication over-use headache (MOH);

4. Beneficiaries that are women of childbearing age have had a negative pregnancy test at baseline;(not required for Nurtec ODT or Qulipta)

5. Beneficiary has 4 or more migraine days per month for at least 3 months;

6. Beneficiary is utilizing prophylactic intervention modalities (e.g. behavioral therapy, physical therapy, life-style modifications) ;

7. Beneficiary has tried and failed at least a month or greater trial of medications from at least 2 different classes from the following list of oral medications:
   a. Antidepressants (e.g. amitriptyline, venlafaxine)
   b. Beta Blockers (e.g. propranolol, metoprolol, timolol, atenolol)
   c. Anti-epileptics (e.g. valproate, topiramate)
   d. Angiotensin converting enzyme inhibitors/angiotensin II receptor blockers (e.g. lisinopril, candesartan)
   e. Calcium Channel Blockers (e.g. verapamil, nimodipine)

8. For Nurtec ODT only:
   a. Beneficiary must NOT be concurrently using a strong CYP3A4 inhibitor;
   b. Beneficiary must NOT have end-stage renal disease (creatinine clearance [CrCl] < 15 mL/min);

9. Initial approvals for up to a 3-month duration for Aimovig, Emgality, Nurtec ODT, Qulipta, or Ajovy monthly dosing; and

10. Initial approvals for up to a 6-month duration for Ajovy quarterly dosing and Vyepti.

Continuation of Coverage (renewal request) (Aimovig, Ajovy, and Emgality 120mg/ml, Nurtec ODT, Qulipta)

1. Beneficiary has demonstrated significant decrease in the number, frequency, and/or intensity of headaches;

2. Beneficiary had experienced an overall improvement in function with therapy;

3. Beneficiary continues to utilize prophylactic intervention modalities (e.g. behavioral therapy, physical therapy, life-style modifications);

04/01/2022
Migraine Therapy
Calcitonin Gene-Related Inhibitors

4. Beneficiaries that are women of childbearing age continue to be monitored for pregnancy status;
5. Beneficiary is not experiencing unacceptable toxicity (e.g. intolerable injection site pain, constipation); AND
6. Length of therapy may be approved for up to 12 months.

B. Treatment of Episodic Cluster Headache in Adults (Emgality 100mg/ml (set of 3))

Initial Criteria for Coverage

1. Beneficiary has a diagnosis of Episodic Cluster Headache with at least two cluster periods lasting from 7 days to 1 year (when untreated) and separated by pain-free remission periods of at least 3 months;
2. Beneficiary is 18 years old or older;
3. Beneficiaries that are women of childbearing age have had a negative pregnancy test at baseline;
4. Beneficiary is utilizing prophylactic intervention modalities (e.g. medication therapy);
5. Beneficiary is receiving no more than 300mg (administered as three consecutive injections of 100mg each) at the onset of the cluster headache period, and then monthly until the end of the cluster headache period; and
6. Initial approvals for up to a 3-month duration.

Continuation of Coverage (renewal request) (Emgality 100mg/ml (set of 3))

1. Beneficiary has demonstrated decreases in the length, number, frequency, and/or intensity of headaches and/or a decrease in the length of the cluster period;
2. Beneficiary had experienced an overall improvement in function with therapy;
3. Beneficiary continues to utilize prophylactic intervention modalities (e.g. behavioral therapy, physical therapy, life-style modifications, medications);
4. Beneficiaries that are women of childbearing age continue to be monitored for pregnancy status;
5. Beneficiary is not experiencing unacceptable toxicity (e.g. intolerable injection site pain, constipation); AND
6. Length of therapy may be approved for up to 12 months

C. Acute Treatment of Migraines (Nurtec ODT 75mg and Ubrelvy 50 mg & 100 mg tablets)

Initial Criteria for Coverage
1. Beneficiary must be ≥ 18 years of age;

2. Beneficiary must have a diagnosis of migraine, with or without aura;

3. Beneficiary must NOT have headache frequency ≥ 15 headache days per month during the prior 6 months;

4. Beneficiary must NOT be concurrently using a strong CYP3A4 inhibitor;

5. Beneficiary must NOT have end-stage renal disease (creatinine clearance [CrCl] < 15 mL/min);

6. Beneficiary must have tried and failed ≥ 1 of the following: NSAID, nonopioid analgesic, acetaminophen, OR caffeinated analgesic combination; AND

7. Beneficiary must have tried and failed, or have contraindication to, ≥ 2 preferred triptans.

**Renewal Criteria**

1. Beneficiary must continue to meet the above criteria;

2. Beneficiary must demonstrate resolution in headache pain or reduction in headache severity, as assessed by prescriber; AND

3. Beneficiary has not have experienced any treatment-restricting adverse effects (e.g., nausea, somnolence, dry mouth).

**References**


<table>
<thead>
<tr>
<th>Date</th>
<th>Change Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>02/26/2019</td>
<td>Criteria effective date</td>
</tr>
<tr>
<td>12/04/2019</td>
<td>Added coverage for Episodic Cluster Headache in Adults</td>
</tr>
<tr>
<td>3/11/2021</td>
<td>Added Ubrelvy</td>
</tr>
<tr>
<td>3/11/2021</td>
<td>Added Nurtec ODT and Vyepti</td>
</tr>
<tr>
<td>04/01/2022</td>
<td>Add coverage for preventative treatment for Nurtec ODT</td>
</tr>
<tr>
<td></td>
<td>Add Qulipta</td>
</tr>
</tbody>
</table>